Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.

Industry News Archive

FDA Approves Atezolizumab + Chemotherapy for Metastatic Non-Squamous NSCLC

On Dec. 3, 2019, the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

Read the corporate announcement.

Read FDA announcement.

Posted 12/04/2019; updated 12/06/2019

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
tops-tennessee.com
Email Us